EMEA-002646-PIP01-19

Table of contents

Key facts

Active substance
  • levocetirizine
  • montelukast
Therapeutic area
  • Oto-rhino-laryngology
  • Pneumology-allergology
Decision number
P/0056/2020
PIP number
EMEA-002646-PIP01-19
Pharmaceutical form(s)
  • Tablet
  • Powder for oral solution
Condition(s) / indication(s)
Treatment of allergic rhinitis
Route(s) of administration
Oral use
Contact for public enquiries
Abbott Laboratories Limited

Tel.  +44 1628644132
E-mail: abbott-EPD-GRA@abbott.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating